Last reviewed 2026-04-20 · How we verify

Frenactil (BENPERIDOL)

Frenactil works by blocking the action of dopamine at the D(2) receptor, which is involved in regulating behavior and motivation.

Frenactil, also known as benperidol, is a small molecule medication that targets the D(2) dopamine receptor. It is used to treat antisocial behavior and is classified as a benperidol drug. The commercial status of Frenactil is unknown, but it is not FDA-approved. Key safety considerations include its half-life of 5.8 hours and bioavailability of 40%. Frenactil's effectiveness and safety profile are not well-documented.

At a glance

Mechanism of action

Think of dopamine as a messenger that helps us feel pleasure and motivation. When Frenactil blocks dopamine at the D(2) receptor, it can help reduce impulsive and aggressive behavior. This is because the D(2) receptor is involved in regulating the brain's reward system and impulse control.

Approved indications

• Antisocial behavior

Common side effects

• Neuroleptic malignant syndrome
• Psychotic symptom

Key clinical trials

• Antipsychotic Induced Structural and Functional Brain Changes (PHASE4)
• Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients (PHASE4)
• Pharmacovigilance in Gerontopsychiatric Patients (PHASE3)
• Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Frenactil CI brief — competitive landscape report
• Frenactil updates RSS · CI watch RSS